Business Wire

DXC Technology Welcomes Brenda Tsai as Chief Marketing and Communications Officer

Share

DXC Technology (NYSE:DXC), a leading technology services company today announced that it has appointed Brenda Tsai as Executive Vice President and Chief Marketing and Communications Officer. Tsai will report to DXC President and Chief Executive Officer Mike Salvino. Tsai will be responsible for leading all areas of the DXC global marketing and communications function.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005122/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brenda Tsai, Executive Vice President and Chief Marketing and Communications Officer, DXC Technology (Photo: Business Wire)

“Brenda is a strategic, result-oriented leader who brings deep marketing experience to DXC,” Salvino said. “She’s an outstanding addition to our leadership team and will play an integral role in helping to drive DXC’s continued transformation and next level of growth.”

“I’m thrilled to join DXC and this accomplished team,” Tsai said. “DXC is in a great position to grow and win in the market and I see the great opportunities and possibilities ahead for further amplifying DXC’s story.”

Tsai has had over 26 years of experience helping complex, global blue-chip companies transform and drive business growth through purpose-driven brand building, data analytics, digital and demand generation. She has worked on a global scale across a range of sectors, including financial services, technology, and manufacturing. Prior to joining DXC, Tsai has held senior roles in top-tier companies, including BNY Mellon, GE and P&G. Tsai holds a BA from Stanford University and an MBA and MA from The University of Pennsylvania.

About DXC Technology
DXC Technology (NYSE:DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy the Enterprise Technology Stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.com.

All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, and no assurance can be given that any goal, plan or result set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. For a written description of these factors, see the section titled “Risk Factors” in DXC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021, and any updating information in subsequent SEC filings. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rich Adamonis, Corporate Media Relations, +1-862-228-3481, radamonis@dxc.com
John Sweeney, Investor Relations, +1-908-315-3665, john.sweeney@dxc.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mundipharma and Vectura announce plans to reformulate flutiform ® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint16.4.2024 11:00:00 CEST | Press release

Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/ The productis an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3 It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1 Work is already under way to source an alternative

Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal16.4.2024 10:30:00 CEST | Press release

Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team. “This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx. “This major medical first lies not only in the technical achievement of Caranx Medical's engine

Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine16.4.2024 10:00:00 CEST | Press release

Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416226137/en/ Arthur D. Little has published Human After All – the latest edition of its strategy and innovation magazine PRISM. (Graphic: Business Wire) The magazine features seven key articles: Optimistic global CEOs focus on people and skills in an AI future - Our lead article shares highlights from the ADL 2024 CEO Insights Study, finding that CEOs are increasingly confident of future economic success. The people-centric lab of the future – how technology and AI can play a key role in driving breakthrough innovation by enabling people to become perfect innovators. The future workforce - Recruiting and retaining vital

Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap16.4.2024 09:32:00 CEST | Press release

Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK. Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum. Ian Jones, Man

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 09:00:00 CEST | Press release

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye